Literature DB >> 14604226

Immunohistochemical expression of E-cadherin in metastatic brain tumors.

Hamisi Kimaro Shabani1, Gaspar Kitange, Keishi Tsunoda, Takeo Anda, Yoshiharu Tokunaga, Shobu Shibata, Makio Kaminogo, Tomayoshi Hayashi, H Ayabe, Masachika Iseki.   

Abstract

The adhesion molecule E-cadherin has been shown to influence malignant transformation of tumors, including local and distant metastases. We examined the expression of E-cadherin to determine its relationship to the development of metastasis in metastatic brain tumors. Immunohistochemistry for E-cadherin and Ki-67 was carried out in 76 formalin-fixed, paraffin-embedded archival specimens of metastatic brain tumors and in 14 corresponding available primary tumors from patients who received treatment for metastatic brain tumors. The primary tumors were mainly lung cancers (51.3%), followed by gastrointestinal tumors (28.9%). E-cadherin was expressed in 62 (81.5%) of 76 cases examined. In metastatic adenocarcinomas, a consistent tendency for E-cadherin expression was noted, regardless of the degree of differentiation or the extent of spread of the disease (P = 0.04). There was a direct correlation between E-cadherin expression and high MIB-1 index in all metastatic brain tumors (P = 0.0007). Pairwise analysis in 14 primary tumors and the corresponding metastatic specimens revealed high E-cadherin and MIB-1 staining in metastatic brain tumors. These results provide a unique association between E-cadherin, systemic metastasis, and proliferation potential in metastatic brain tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604226     DOI: 10.1007/bf02478941

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  7 in total

1.  Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis.

Authors:  Yawara Omoto; Masafumi Kurosumi; Yasuo Hozumi; Hanako Oba; Kaori Kawanowa; Hiroyuki Takei; Yoshikazu Yasuda
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

Review 2.  Pathobiology of brain metastases.

Authors:  N Nathoo; A Chahlavi; G H Barnett; S A Toms
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 3.  Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options.

Authors:  Meysam Yousefi; Tayyeb Bahrami; Arash Salmaninejad; Rahim Nosrati; Parisa Ghaffari; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2017-09-18       Impact factor: 6.730

4.  E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model.

Authors:  Jin Young Yoo; Seung-Ho Yang; Jung Eun Lee; Deog Gon Cho; Hoon Kyo Kim; Sung Hwan Kim; Il Sup Kim; Jae Taek Hong; Jae Hoon Sung; Byung Chul Son; Sang Won Lee
Journal:  J Neurooncol       Date:  2012-05-11       Impact factor: 4.130

5.  Immunohistochemical Expression of DCUN1D1 in Non-small Cell Lung Carcinoma: Its Relation to Brain Metastasis.

Authors:  Jinyoung Yoo; Seong-Hak Lee; Kwang-Il Lym; Sonya Youngju Park; Seung-Ho Yang; Chang-Young Yoo; Ji-Han Jung; Seok-Jin Kang; Chang-Suk Kang
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

Review 6.  Role of the blood-brain barrier in the formation of brain metastases.

Authors:  Imola Wilhelm; Judit Molnár; Csilla Fazakas; János Haskó; István A Krizbai
Journal:  Int J Mol Sci       Date:  2013-01-11       Impact factor: 5.923

7.  Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin.

Authors:  Anja Kafka; Davor Tomas; Vili Beroš; Hrvoje Ivan Pećina; Martina Zeljko; Nives Pećina-Šlaus
Journal:  Int J Mol Sci       Date:  2014-06-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.